Search Result

Results for "

SCID mice

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) ADC Payload (1) Akt (3) Androgen Receptor (2) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (18) Autophagy (1) Bacterial (1) Bcl-2 Family (4) BCL6 (1) Biochemical Assay Reagents (1) BMI1 (1) Bombesin Receptor (1) Btk (2) c-Met/HGFR (1) Carboxypeptidase (1) Casein Kinase (1) Caspase (2) CD19 (1) Claudin (1) CXCR (2) Discoidin Domain Receptor (1) DNA/RNA Synthesis (2) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (2) Environmental Pollutants (1) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (1) FGFR (1) FLT3 (3) Folate Receptor (FR) (1) HCV (1) HDAC (1) Histone Acetyltransferase (1) Histone Methyltransferase (2) HSP (1) Integrin (1) JAK (1) Kinesin (2) Ligands for Target Protein for PROTAC (1) Liposome (1) MDM-2/p53 (5) MicroRNA (1) Microtubule/Tubulin (4) Mitochondrial Metabolism (1) MMP (1) mTOR (1) NF-κB (2) NO Synthase (1) Oxidative Phosphorylation (1) PAI-1 (1) Parasite (1) PARP (1) PDGFR (1) PERK (1) PROTACs (6) Pyroptosis (1) Ras (1) SARS-CoV (1) Ser/Thr Protease (1) SOD (1) STAT (1) TGF-β Receptor (1) TNF Receptor (2) Topoisomerase (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (51) Cardiovascular Disease (4) Infection (3) Inflammation/Immunology (3) Metabolic Disease (1)

By Targets:

ADC Antibody (1)

ADC Payload (1)

Akt (3)

Androgen Receptor (2)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (18)

Autophagy (1)

Bacterial (1)

Bcl-2 Family (4)

BCL6 (1)

Biochemical Assay Reagents (1)

BMI1 (1)

Bombesin Receptor (1)

Btk (2)

c-Met/HGFR (1)

Carboxypeptidase (1)

Casein Kinase (1)

Caspase (2)

CD19 (1)

Claudin (1)

CXCR (2)

Discoidin Domain Receptor (1)

DNA/RNA Synthesis (2)

Drug-Linker Conjugates for ADC (1)

E1/E2/E3 Enzyme (2)

Environmental Pollutants (1)

Epigenetic Reader Domain (1)

Estrogen Receptor/ERR (1)

FGFR (1)

FLT3 (3)

Folate Receptor (FR) (1)

HCV (1)

HDAC (1)

Histone Acetyltransferase (1)

Histone Methyltransferase (2)

HSP (1)

Integrin (1)

JAK (1)

Kinesin (2)

Ligands for Target Protein for PROTAC (1)

Liposome (1)

MDM-2/p53 (5)

MicroRNA (1)

Microtubule/Tubulin (4)

Mitochondrial Metabolism (1)

MMP (1)

mTOR (1)

NF-κB (2)

NO Synthase (1)

Oxidative Phosphorylation (1)

PAI-1 (1)

Parasite (1)

PARP (1)

PDGFR (1)

PERK (1)

PROTACs (6)

Pyroptosis (1)

Ras (1)

SARS-CoV (1)

Ser/Thr Protease (1)

SOD (1)

STAT (1)

TGF-β Receptor (1)

TNF Receptor (2)

Topoisomerase (1)

Transmembrane Glycoprotein (1)

By Research Areas:

Cancer (51)

Cardiovascular Disease (4)

Infection (3)

Inflammation/Immunology (3)

Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153065

KIF18A-IN-6	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC₅₀ of 0.016 μM against KIF18A microtubule-dependent ATPase activity .

HY-P2300

Cyclo(Arg-Gly-Asp-D-Phe-Cys) 2 Publications Verification Cyclo(RGDfC)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .

HY-158113

CBPD-409	Histone Acetyltransferase PROTACs	Cancer
CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC₅₀ of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC₅₀s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) .

HY-153066

VLS-1272 KIF18A-IN-7	Kinesin Microtubule/Tubulin Apoptosis	Cancer
VLS-1272 (Compound 22) is an orally active KIF18A inhibitor that binds to the KIF18A-microtubule complex in an ATP-noncompetitive manner (IC₅₀ = 41 nM), blocking its ATPase activity and inhibiting microtubule translocation. This leads to abnormal accumulation of KIF18A at spindle poles, disrupting chromosome alignment and inducing mitotic arrest and apoptosis in CIN ^High tumor cells (e.g., ovarian cancer OVCAR-3, breast cancer JIMT-1). VLS-1272 is a promising candidate for anti-tumor research .

HY-B1817

Zinc acetate	Environmental Pollutants Apoptosis Biochemical Assay Reagents HSP	Cardiovascular Disease Inflammation/Immunology Cancer
Zinc acetate acts as an immune response modulator. Zinc acetate enhances the expression of HSP-70 mRNA. Zinc acetate restores the proliferation and cytokine production capacities of splenocytes. Zinc acetate reduces the Apoptosis level of splenocytes in endotoxemic mice. Zinc acetate increases plasma zinc levels and improves survival rates in mice with LPS-induced lethal endotoxemia. Zinc acetate induces rapid death of prostate cancer cell lines in vitro. Zinc acetate inhibits the growth of prostate cancer xenografts in SCID mice. Zinc acetate can be used in endotoxemia research .

HY-172760

CIM-834	SARS-CoV	Infection
CIM-834 is an orally effective inhibitor of SARS-CoV-2 membrane protein. CIM-834 can prevent the assembly of infectious virus particles without inhibiting the synthesis of viral RNA. CIM-834 can reduce the viral titer in the lungs of SCID mice infected nasally with SARS-CoV-2, block the spread of SARS-CoV-2 among Syrian hamsters, and inhibit the replication of SARS-CoV-2 (including variants) and SARS-CoV. CIM-834 can be used in related research on COVID-19 .

HY-W018723

4-Aminobenzamidine dihydrochloride 1 Publications Verification p-Aminobenzamidine dihydrochloride	Ser/Thr Protease PAI-1	Cardiovascular Disease Cancer
4-Aminobenzamidine (p-Aminobenzamidine) dihydrochloride is a strong trypsin inhibitor. 4-Aminobenzamidine dihydrochloride acts as an orally active urokinase type plasminogen activator (uPA) inhibitor (K_i=82 μM). 4-Aminobenzamidine dihydrochloride can be used for cardiovascular diseases and anti-tumor study .

HY-P991200

OM-7D3-B3	HCV Claudin	Infection
OM-7D3-B3 is an antibody-based antiviral agent targeting the tight junction protein CLDN1 (K_d=4 nM). By binding to the first extracellular domain of CLDN1, OM-7D3-B3 disrupts the formation of the CLDN1-CD81 co-receptor complex, thereby effectively inhibiting the entry of hepatitis C virus (HCV). OM-7D3-B3 not only prevents de novo and chronic HCV infections in humanized liver chimeric mice and uPA-SCID mice transplanted with human livers, but also exhibits favorable safety with no toxic effects observed. OM-7D3-B3 serves as a critical tool for research on HCV infection mechanisms and antiviral drug development .

HY-P0132

YIGSR 1 Publications Verification Laminin Fragment 929-933	NO Synthase	Cancer
YIGSR (Laminin Fragment 929-933) is a polypeptide that inhibits tumor growth and metastasis of leukemia cells. YIGSR specifically binds to the 67kDa laminin receptor and regulates the expression of eNOS in endothelial cells. YIGSR can be used in leukemia-related research .

HY-148819A

NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT hydrochloride	ADC Payload Topoisomerase	Cancer
NH2-bicyclopentane-7-MAD-MDCPT hydrochloride (Formula I) is a topoisomerase I (TOP1) inhibitor. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is applicable to the synthesis of the ADC ABBV-969. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is used in research on lung adenocarcinoma and melanoma .

HY-P99588

Stamulumab 1 Publications Verification MYO-029	TGF-β Receptor	Metabolic Disease
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .

HY-158421

MS-L6	Oxidative Phosphorylation Mitochondrial Metabolism	Cancer
MS-L6 is a potent inhibitor of oxidative phosphorylation (OXPHOS) that can acts as electron transport chain complexes I (ETC-I) combining inhibition of NADH oxidation and uncoupling effect .

HY-125858

MI-1061 3 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-P99653A

Ianalumab (FUT8-KO) VAY-736 (FUT8-KO)	TNF Receptor Apoptosis NF-κB	Inflammation/Immunology Cancer
Ianalumab (VAY-736) (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose depletion enhances its B cell clearance capacity. Ianalumab (FUT8-KO) competitively blocks the binding of BAFF to BAFF-R, inhibits the BAFF-mediated alternative NF-κB pro-survival signaling pathway, and abrogates the apoptotic (apoptosis) protective effect of BAFF on cancer cells. Ianalumab (FUT8-KO) can be used in research related to primary Sjögren's syndrome and chronic lymphocytic leukemia .

HY-176761

NSC647889	Apoptosis Autophagy Caspase mTOR	Cancer
NSC647889 is an apoptosis and autophagy inducer. NSC647889 induces apoptosis, inhibits mTOR pathway and abrogates DNA synthesis. NSC647889 triggers LC3-positive vesicle formation, modulates AKT and 4EBP1 phosphorylation and shows heightened caspase-3 activation in multicellular spheroids. NSC647889 can be used for the research of solid cancer tumour, head-neck carcinoma, and colorectal cancer .

HY-177760

PrCP-7414	Carboxypeptidase Apoptosis Akt	Cancer
PrCP-7414 is a prolyl carboxypeptidase (PRCP) inhibitor. PrCP-7414 blocks PRCP-mediated activation of the IGF1R/HER3 signaling pathway and subsequent AKT activation. PrCP-7414 exhibits pro-apoptotic, anti-tumor and synergistic cytotoxic activities, and inhibits the proliferation and survival of triple-negative breast cancer cells. PrCP-7414 can be used for the research of breast cancer .

HY-169240

MX69-102	MDM-2/p53	Cancer
MX69-102 (compound MX69-102) is an MDM-2/p53 inhibitor, inducing MDM2 degradation, resulting in p53 activation and cancer cell apoptosis. MX69-102 shows effective inhibition on xenografted human MDM2-overexpressing ALL in SCID mice. .

HY-149428

AD4 1 Publications Verification	PROTACs	Cancer
AD4 is an artemisinin derivative that is a proteolytic targeting chimera (PROTAC) targeting PCLAF. AD4 can effectively degrade PCLAF in RS4;11 cells (IC₅₀: 0.6 nM), thereby activating the p21/Rb axis and exerting anti-tumor activity. AD4 also prolonged survival of RS4;11-transplanted NOD/SCID mice, with in vivo efficacy .

HY-P99595

Sirtratumab vedotin AGS15E; ASG-15ME; 1vcMMAE	Antibody-Drug Conjugates (ADCs)	Cancer
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker .

HY-128866

TBAJ-876	Bacterial	Infection
TBAJ-876 is an orally active diarylquinoline anti-Mycobacterium agent. TBAJ-876 regulates energy metabolism by targeting the c and ε subunits of Mycobacterium tuberculosis F-ATP synthase, exerts bactericidal activity against replicating Mycobacterium tuberculosis, and retains activity against strains carrying the Rv0678 mutation. TBAJ-876 undergoes N-demethylation in vivo to form its major active metabolite TBAJ-876-M3, which has lower lipophilicity and hERG potassium channel binding affinity. TBAJ-876 is well tolerated in BALB/c mice and significantly reduces the colony-forming units of Mycobacterium tuberculosis in the lungs. In addition, TBAJ-876 exhibits inhibitory activity against Mycobacterium abscessus, reduces bacterial loads in the lungs and spleens of infected mice, and shows no antagonistic effect when used in combination with common antibiotics. TBAJ-876 can be used in studies related to tuberculosis and Mycobacterium abscessus pulmonary diseases .

HY-114311

FGFR1/DDR2 inhibitor 1 2 Publications Verification	FGFR Discoidin Domain Receptor	Cancer
FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC₅₀ values of 31.1 nM and 3.2 nM, respectively. Antitumor activity .

HY-175455

LYA914	PROTACs Androgen Receptor Akt	Cancer
LYA914 is an orally active AR/AR-V7 PROTAC degrader. LYA914 targets the proteolytic degradation of the conserved DNA binding domain (DBD) of the androgen receptor (AR). LYA914 exhibits potent antiproliferative effects in Enzalutamide (HY-70002)-insensitive/resistant cells. LYA914 inhibits tumor growth in VCaP/LNCaP tumor mouse models. LYA914 can be used to study castration-resistant prostate cancer (CRPC). (Pink: AR-DBD ligand-1: HY-175456, Blue: Thalidomide: HY-14658, Pink + Black: AR-DBD ligand-Linker Conjugate 1: HY-175457, Black: Boc-piperidine-oxopiperidin: HY-175458) .

HY-175541

TQ-3959	PROTACs Btk	Cancer
TQ-3959 is an orally active BTK PROTAC degrader, with a DC₅₀ of 14.6 nM. TQ-3959 exerts antiproliferative activity against both wild-type BTK and C481S mutant BTK cell lines. TQ-3959 exhibits tumor growth inhibition in female NOD-SCID mice bearing TMD-8 xenografts. TQ-3959 can be used in the research on B-cell malignancies such as lymphoma.(Pink: BTK ligand (HY-150885), Blue: CRBN Ligand (HY-W733888), Black: Linker (HY-W061884), E3 ligase ligand-linker conjugate (HY-175545)) .

HY-120105

NSC666715	DNA/RNA Synthesis Apoptosis MDM-2/p53 Bcl-2 Family Caspase PARP	Cancer
NSC666715 is a DNA polymerase β (Pol-β) inhibitor. NSC666715 directly and specifically interacts with Pol-β, interferes with its binding to damaged DNA, blocks its dRP lyase activity, and inhibits Pol-β-mediated SN- and LP-BER. NSC666715 induces AP site accumulation and S-phase cell cycle arrest, and triggers senescence and apoptosis (apoptosis) via the p53/p21 pathway in colorectal cancer cells. NSC666715 enhances TMZ (HY-17364)-induced DNA damage, senescence and apoptosis, and potentiates the cytotoxicity of TMZ. NSC666715 inhibits tumor growth in colon cancer xenograft models. NSC666715 can be used in research related to colorectal cancer .

HY-176561

IOR-160	Casein Kinase HDAC	Cancer
IOR-160 is a dual inhibitor of casein kinase 2 (CK2) and HDACs. IOR-160 exhibits high selectivity for CK2 (IC₅₀ = 1.7 nM) and broad inhibitory activity against HDAC (HDAC 1, 2, 3, and 6 with IC₅₀s of 3.3 nM, 24.0 nM, 3.9 nM, and 13.0 nM, respectively, with low activity for HDAC8). IOR-160 modulates key cellular signaling pathways by inhibiting AKT phosphorylation and increasing acetylated α-tubulin. IOR-160 inhibits tumor growth and reduces tumor burden through dual CK2/HDAC inhibition. IOR-160 is indicated for use in triple-negative breast cancer research .

HY-174129

TM471-1	Btk Apoptosis	Cancer
TM471-1 is an orally active and covalent Bruton's tyrosine kinase (BTK) inhibitor with IC₅₀ values of 1.3 nM (BTK ^WT), >40,000 nM (BTK ^C481S), 7.9 nM (TEC) and 12.4 nM (TXK). TM471-1 inhibits cell growth in vivo and in vitro, arrests cell cycle at G0/G1 phase and induces cell apoptosis .

HY-P991542

GBR-401	CD19	Cancer
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .

HY-174437

FLT3-IN-32	FLT3 Apoptosis	Cancer
FLT3-IN-32 is a potent and orally active FLT3 inhibitor. FLT3-IN-32 shows high selectivity for FLT3 and efficiently inhibits FLT3-activating mutations and induces apoptosis. FLT3-IN-32 shows good tolerability in non-tumor bearing mice. FLT3-IN-32 demonstrates outstanding anti-tumor efficacy in MV4-11 bearing NOD/SCID mice, prolonging the survival noticeably. FLT3-IN-32 can be used for the research of acute myeloid leukemia .

HY-112417

Ki11502	PDGFR FLT3 Apoptosis Akt PERK Bcl-2 Family	Cardiovascular Disease Cancer
Ki11502 is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGF β/α receptors with IC₅₀ values less than 10 nM. Ki11502 selectively inhibits PDGF β receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Ki11502 can induce Apoptosis) and exhibits profound antiproliferative effects on select subsets of leukemia, including those with Imatinib (HY-15463) resistant mutations. Ki11502 is highly suitable for studying the role of PDGF in vascular diseases, particularly the role of proteoglycans in atherosclerosis .

HY-175610

PROTAC FLT3/JAK2/BRD4 Degrader-1	PROTACs FLT3 JAK Epigenetic Reader Domain	Cancer
PROTAC FLT3/JAK2/BRD4 Degrader-1 is a PROTAC degrader that target FLT3, JAK2, and BRD4 with DC₅₀ values of 5.23, 0.678, and 1.17 nM, respectively. PROTAC FLT3/JAK2/BRD4 Degrader-1 exhibits potent antiproliferative activity against MV4;11 cells (IC₅₀ = 0.79 nM) and FLT3 mutant-transformed Ba/F3 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 induces apoptosis in MV4;11 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 demonstrates significant anti-tumor efficacy in the MV4;11 xenograft model established in NOD SCID mice. PROTAC FLT3/JAK2/BRD4 Degrader-1 can be used for the study of acute myeloid leukemia (AML). (Pink: FLT3/JAK2/BRD4 ligand (HY-175611), Blue: CRBN Ligand (HY-W087383), Black: Linker, E3 ligase ligand-linker conjugate (HY-W897939)) .

HY-P10775A

BT1769 acetate	MMP	Cancer
BT1769 acetate is a conjugate and antitumor agent targeting MT1-MMP, with a K_d value of 3.35 nM against human targets. BT1769 acetate exhibits favorable pharmacokinetic properties. BT1769 acetate specifically binds to MT1-MMP via its bicyclic peptide component, delivering the cytotoxic agent MMAE (HY-15162) to antigen-expressing cells. It effectively inhibits tumor growth, induces complete responses, and significantly prolongs event-free survival in osteosarcoma patient-derived xenograft models. BT1769 acetate shows extremely low activity in Ewing sarcoma models and can be used in osteosarcoma-related research .

HY-P991433

BIIB036	TNF Receptor	Cancer
BIIB036 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF12A/Fn14. BIIB036 inhibits the growth of patient-derived primary colorectal tumors in SCID mice .

HY-168270

PROTAC ER Degrader-11	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ER Degrader-11 (Example 26-1) is a potent PROTAC ER degrader, with the IC₅₀ of 0.66 nM. PROTAC ER Degrader-11 plays an important role in cancer research(Sturcture Note:(Blue: Cereblon ligand (HY-W797329), Black: linker (HY-W262798)；Pink: ER ligand (HY-168271)) .

HY-172617

APD-94	BMI1 Microtubule/Tubulin Apoptosis	Cancer
APD-94 is a dual inhibitor targeting tubulin and Bmi-1. APD-94 interfers tubulin normal polymerization. APD-94 suppresses the expression of Bmi-1. APD-94 causes cell cycle arrest at the G2/M phase in cancer cells and induces apoptosis, thus inhibiting cancer cell proliferation. APD-94 represses the growth of HT29 cell xenografts in NOD/SCID mice. APD-94 can be used for colorectal cancer study .

HY-118748

Suprafenacine SRF	Microtubule/Tubulin	Cancer
Suprafenacine is a cell permeable, tubulin-destabilizing molecule which bind microtubules at the colchicine-binding site and inhibit polymerization. Suprafenacine can induce G2/M cell cycle arrest and apoptosis, and can be used for cancer research .

HY-164039

Talorasib	Ras	Cancer
Talorasib (compound 1-2) has antitumor activity .

HY-125858A

MI-1061 TFA 3 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
MI-1061 TFA is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 TFA potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-172885

TRBP-IN-1	DNA/RNA Synthesis MicroRNA Apoptosis Pyroptosis	Cancer
TRBP-IN-1 (Compound 13j) is an orally active TAR RNA binding protein 2 (TRBP) inhibitor (IC₅₀: 12.72 μM). TRBP-IN-1 has significant anti-hepatocellular carcinoma (HCC) activity and can inhibit the proliferation and metastasis of HCC cells (HCCLM3 cells (IC₅₀: 18.96 μM); SK-Hep-1 cells (IC₅₀: 16.45 μM)). TRBP-IN-1 regulates miRNA biogenesis and inhibits oncogenic miRNA expression by targeting TRBP. TRBP-IN-1 induces apoptosis and pyroptosis in HCC cells by inhibiting the level of miRNA. TRBP-IN-1 can be used for targeted therapy research of HCC .

HY-P10301

CXCL9(74-103)	CXCR	Cancer
CXCL9(74-103) is a derivative peptide of CXCL9 that has a high affinity for glycosaminoglycans (GAGs) and can bind to GAGs. CXCL9(74-103) possesses anti-angiogenic properties, capable of reducing EGF, VEGF165, and FGF-2-mediated angiogenesis processes in vitro, without exhibiting cytotoxicity .

HY-172954

Androgen receptor ligand 1	Androgen Receptor Ligands for Target Protein for PROTAC	Cancer
Androgen receptor ligand 1 is an androgen receptor (AR) ligand. Androgen receptor ligand 1 binds to CRBN E3 ligase via a linker to form an AR PROTAC degrader. Androgen receptor ligand 1 can be used in the study of prostate cancer .

HY-P991639

BIW-8962	Apoptosis	Cancer
BIW-8962 is a humanized anti-ganglioside GM2 antibody. BIW-8962 exhibits ADCC/CDC activity against multiple myeloma cells. BIW-8962 demonstrates potent anti-tumor activity in mouse xenograft models. BIW-8962 is indicated for research in myeloma and other cancers .

HY-163483

ELQ-598	Parasite	Others
ELQ-598, as a prodrug, is converted into the active drug ELQ-596 upon oral administration. ELQ-598 demonstrates potent parasitic growth inhibition capabilities (IC₅₀= 37 nM). ELQ-598 also shows low toxicity towards human cells (IC₅₀= 19 μM). ELQ-598 can be used for research into babesiosis .

HY-13846

BM-1074	Bcl-2 Family Apoptosis	Cancer
BM-1074 is a potent and specific Bcl-2/Bcl-xL inhibitor with K_i values of < 1 nM and IC₅₀ values of 1.8 nM and 6.9 nM for Bcl-2 and Bcl-xL, respectively. BM-1074 induces apoptosis, and exhibits antiproliferative activity against four small-cell lung cancer cell lines (H146, H1963, H187 and H1417) with IC₅₀ values of 1-2 nM .

HY-148640

WK500B	BCL6 MDM-2/p53 Histone Methyltransferase CXCR Apoptosis	Cancer
WK500B is a potent and orally active BCL6 inhibitor with a K_D of 1.61 μM. WK500B engages intracellular BCL6 and disrupts BCL6‑corepressor interactions to reactivate BCL6 target genes. WK500B exerts cytotoxicity against diffuse large B‑cell lymphoma cells and induces apoptosis and cell cycle arrest. WK500B suppresses germinal center formation in C57BL/6 mice and DLBCL tumor growth in SCID xenograft models without observable toxicity. WK500B can be used for the study of diffuse large B‑cell lymphoma (DLBCL) .

HY-P992146

Zevontabart MYTX-011 Antibody; Q-397	ADC Antibody c-Met/HGFR	Cancer
Zevontabart (MYTX-011 Antibody; Q-397) is a pH-dependent anti-c-MET antibody. Zevontabart regulates the trafficking process of c-MET to reduce receptor recycling, and enhances its own endocytosis and accumulation in c-MET-expressing cells. Zevontabart induces cytotoxicity in solid tumor cells and exerts anti-tumor activity in a non-small cell lung cancer xenograft mouse model. Zevontabart can be used to synthesize ADC, such as: MYTX-011. Zevontabart can be used in studies related to non-small cell lung cancer, with its corresponding isotype control being Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-182793

MLL1-IN-1	Histone Methyltransferase	Cancer
MLL1-IN-1 is an orally active MLL1 inhibitor with an IC₅₀ of 0.043 μM. MLL1-IN-1 induces Menin protein degradation and inhibits the proliferation of leukemia cells. MLL1-IN-1 can induce tumor regression in leukemia-bearing mice. MLL1-IN-1 is useful for research into MLL1-associated leukemia .

HY-P992004

KHK2805 RA15-7, HuRA15-7Acc	Folate Receptor (FR)	Cancer
KHK2805 (RA15-7) is a humanized antibody against folate receptor α (FOLR1), with a K_d of 0.647 nM for human FOLR1. KHK2805 binds to a unique epitope of FOLR1 and mediates antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against FOLR1-expressing cells. KHK2805 exhibits cytotoxicity against both ovarian cancer cells and Platinum (HY-W096169D)-resistant ovarian cancer cells. KHK2805 can be used for the research of tumors such as ovarian cancer .

HY-122275

A-371191	Bcl-2 Family	Cancer
A-371191 is a selective Bcl-XL antagonist with a K_i <0.5 μM, and also acts as a mitochondria-targeting agent and chemosensitizer. A-371191 restores the sensitivity of cancer cells overexpressing Bcl-XL to Cisplatin (HY-17394) and Doxorubicin (HY-15142A). A-371191 reduces tumor volume in mice with intraperitoneal tumors. A-371191 can be used in the research of acute myeloid leukemia .

HY-P11768

AMBA	Bombesin Receptor	Cancer
AMBA is a gastrin-releasing peptide receptor (GRPR, BB2, BRS-2) ligand with a human IC₅₀ of 0.82 nM and a human K_i of 0.65 nM. AMBA binds to GRPR with high specificity and high affinity, and undergoes receptor-mediated endocytosis, which retains the conjugated radiometal in target cells. AMBA is applicable for the research of prostate cancer .

HY-P992291

Anti-PL2L60 Antibody (KAO3)	Apoptosis	Cancer
Anti-PL2L60 Antibody (KAO3) is a PL2L60-targeting antibody. Anti-PL2L60 Antibody (KAO3) binds to PL2L60 expressed on tumor cell surfaces, blocking its tumor-promoting functions. Anti-PL2L60 Antibody (KAO3) arrests tumor cell cycle and induces cancer cell apoptosis. Anti-PL2L60 Antibody (KAO3) activates complement to mediate tumor cell lysis. Anti-PL2L60 Antibody (KAO3) can be used for the research of lymphoma, breast cancer, lung cancer, cervical cancer, colon cancer, and melanoma^[1].

Cat. No.	Product Name	Target	Research Area